The Obesity Race Has a New Contender

Everyone knows Novo Nordisk and Eli Lilly are fighting for dominance in the GLP-1 obesity market. That duopoly narrative is so well-worn it’s practically a cliché on Wall Street.

But here’s what the headlines keep glossing over: a clinical-stage biotech out of San Diego may be building the most strategically differentiated obesity pipeline in the entire sector — and it’s doing it with a single molecule.

That company is Viking Therapeutics (NASDAQ: VKTX). And the story is worth a close look.

What Viking Actually Does

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

Its lead asset is VK2735 — a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders.

In plain English: it’s in the same class as Mounjaro and Zepbound — drugs that have reshaped the global pharmaceutical landscape. The key difference? Viking believes that VK2735 is differentiated as it represents the only option utilizing the same dual-acting GLP-1 and GIP co-agonist molecule in both a subcutaneous and an oral formulation.

That flexibility — shot or pill, same molecule — is a potentially significant competitive edge.

The Data That Matters

Viking has stacked up an impressive data trail. Starting with the injectable formulation:

• The 13-week Phase 2 VENTURE trial met its primary and secondary endpoints, showing mean body-weight reductions up to 14.7% from baseline with no plateau.
• The Phase 3 VANQUISH-1 study is a randomized, double-blind, placebo-controlled multicenter trial evaluating VK2735 subcutaneously once weekly for 78 weeks, enrolling approximately 4,650 adults with obesity or overweight with at least one comorbid condition.
• Viking Therapeutics completed enrollment in the Phase 3 VANQUISH-2 trial of VK2735 in March 2026.

The oral pill data is equally compelling. The Phase 2 VENTURE-Oral Dosing trial showed up to 12.2% mean weight loss at 13 weeks with a strong dose response, and an exploratory cohort maintained reductions after down-titration — supporting a potential maintenance strategy.

On a key secondary endpoint, up to 97% of VK2735-treated participants achieved at least 5% weight loss versus 10% on placebo, and up to 80% achieved at least 10% weight loss compared to just 5% on placebo.

Oral VK2735 is now slated to advance into Phase 3 for obesity in Q3 2026. That’s a significant inflection point on the horizon.

The Balance Sheet Holds Up

For a clinical-stage biotech — a category known for cash burn — Viking’s financial positioning is notably strong.

The company reported a cash position of $706 million at quarter end (Q4 2025). Management has stated the balance sheet provides sufficient resources to enable development of VK2735 through the VANQUISH Phase 3 clinical trials, and to continue development of additional clinical programs.

That runway matters. It means Viking can execute without being forced into dilutive financing at inopportune moments.

Beyond VK2735: The Pipeline Depth

Viking isn’t a one-trick pony. The pipeline extends in two meaningful directions.

The company believes dual activation of the amylin and calcitonin receptors could represent an attractive treatment option for patients who are not candidates for GLP-1 therapeutics, and has been developing a series of potent agonists that could play an important role as both single agents or in combination with GLP-1 or dual GLP-1/GIP agonists.

In the rare disease space, Viking is also developing VK0214 for the potential treatment of X-linked adrenoleukodystrophy (X-ALD), which in a Phase 1b trial was shown to be safe and well-tolerated while driving significant reductions in plasma levels of very long-chain fatty acids.

Multiple shots on goal. That’s how you de-risk a clinical-stage biotech thesis.

The Risks Are Real — And Worth Naming

No editorial on a clinical-stage biotech would be complete without an honest look at downside.

• Trial risk: Phase 3 data could disappoint. Phase 2 success does not guarantee Phase 3 success — that’s a biotech constant.
• Competition: Viking is navigating a challenging environment with its GLP-1 candidate VK2735 amid intense competition. Lilly and Novo are entrenched incumbents with massive commercial infrastructure.
• Tolerability questions: Almost all adverse events in oral trials were mild or moderate in severity, though nausea occurred in 58% of VK2735-treated patients and vomiting arose in 26%. Managing GI side effects at scale will be a commercial challenge.
• Manufacturing complexity: Analysts have noted that Viking’s drug may require two- to four-times higher active pharmaceutical ingredient than tirzepatide to reach comparable placebo-adjusted weight loss — a potential cost and supply chain pressure point.
• No revenue yet: For a clinical-stage company with no current revenue, everything rests on the success of its metabolic and endocrine pipeline rather than on existing financials.

Why This Stock Belongs on the Radar

The obesity drug market is not a winner-take-all market. It’s a multi-hundred-billion-dollar addressable opportunity — and history suggests there will be more than two or three winners.

What makes Viking interesting right now is the convergence of several catalysts at once: two ongoing Phase 3 trials fully enrolled, oral Phase 3 initiation approaching in Q3 2026, maintenance dosing data expected, and a deep enough balance sheet to see it through.

Providing patients the option to remain on the same active compound throughout their treatment may reduce the potential for undesired side effects compared with options that involve switching between different therapeutic agents — and could lead to improved adherence and better long-term outcomes.

That patient-centric differentiation is the kind of story that resonates with both clinicians and payers. And if the Phase 3 VANQUISH data delivers, the conversation around VKTX may shift considerably.

It’s not a sure thing. Nothing in biotech ever is. But as a high-conviction watch-list name in the most competitive and well-funded sector in all of healthcare — Viking Therapeutics may be exactly the kind of rising star worth following closely.

This editorial is for informational purposes only and does not constitute financial or investment advice. All content is based on publicly available information. Past clinical results may not predict future outcomes. Investing in clinical-stage biotechnology companies involves significant risk, including the potential loss of principal. Always conduct your own due diligence before making any investment decisions.